|Awarded On||August 19, 2020|
|Title||CPRIT Early Clinical Investigator Award|
|Award Mechanism||Early Clinical Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Chad Tang|
|Cancer Sites||Colorectal, Kidney and Renal Pelvis, Prostate|
Oligometastatic (oligomet) disease represents a newly proposed disease state that is hypothesized to be an intermediate state of metastatic disease that benefits from definitive local therapy. Our group was the first to show that definitive treatment of oligomet patients with radiation results in an overall survival benefit. We are currently accruing to the follow up EXTEND trial, a biomarker-heavy basket study funded by CPRIT, and the unfunded oligomet RCC trial. With this grant we aim to capitalize on our momentum to conduct unfunded tissue correlatives collected from these trials and to initiate the next investigator-initiated oligomet trial. 1.Analyze the genetic landscape of oligomet di...